ReviewAnnals of the New York Academy of Sciences2014
Sequencing the head and neck cancer genome: implications for therapy.
Review in Annals of the New York Academy of Sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients.NPJ precision oncology · 2026Article
- The Impact of Senescence-Associated Secretory Phenotype (SASP) on Head and Neck Cancers: From Biology to Therapy.Cancers · 2025Review
- Potential Prognostic Role of Protein Kinase D Isoforms in Head and Neck Cancers.International journal of molecular sciences · 2024Article
- Mutation detection in saliva from oral cancer patients.Oral oncology · 2024Article
- Hypomethylated SPANXA1/A2 promotes the metastasis of head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2020Article
- Review
- Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.Scientific reports · 2020Article
- Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines.SLAS discovery : advancing life sciences R & D · 2020Article
- Immunometabolic Alterations by HPV Infection: New Dimensions to Head and Neck Cancer Disparity.Journal of the National Cancer Institute · 2019Review
- High Content Screening Characterization of Head and Neck Squamous Cell Carcinoma Multicellular Tumor Spheroid Cultures Generated in 384-Well Ultra-Low Attachment Plates to Screen for Better Cancer Drug Leads.Assay and drug development technologies · 2019Article
- A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer.Diagnostics (Basel, Switzerland) · 2018Article
- DDB2 regulates Epithelial-to-Mesenchymal Transition (EMT) in Oral/Head and Neck Squamous Cell Carcinoma.Oncotarget · 2018Article
- PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.Oncotarget · 2018Article
- Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer.Seminars in radiation oncology · 2018Review
- EGFR-Targeted Magnetic Nanovectors Recognize,ACS medicinal chemistry letters · 2017Article
- Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.Nature genetics · 2017Article
- Review
- Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma.Oncotarget · 2017Review
- Applications of molecular testing in surgical pathology of the head and neck.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017Review
- PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a disease with significant morbidity and mortality. The advancement of next-generation sequencing technologies now enables the landscape of genetic alterations in HNSCCs to be deciphered. In this review, we describe the mutation spectrum discovered in HNSCCs, especially human papilloma virus-associated and/or tobacco smoke exposure-associated HNSCCs. We also describe related research from two independent investigators and from the Cancer Genome Atlas. Emphasis is placed on the therapeutic implications of genes frequently altered in HNSCCs (i.e., TP53, PIK3CA, and NOTCH1) and their corresponding pathways, with a particular focus on recent findings of Notch signaling pathway activation in HNSCC. We also discuss the application of integrated genomic pathway-based analysis for precision cancer therapy in HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.